Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biogen
Biotech
Biogen pays Stoke $165M, bagging Dravet drug to fire up pipeline
Biogen is paying Stoke $165 million upfront for ex-U.S. rights to a phase 3-ready molecule that could become the first disease-modifying Dravet drug.
Nick Paul Taylor
Feb 18, 2025 9:28am
Biogen axes asset from $7.3B buyout, plus Alzehimer’s prospect
Feb 12, 2025 9:53am
Biogen taps Royalty for $250M to fund phase 3 lupus program
Feb 12, 2025 8:10am
Atalanta loads crossbow with $97M, 2 Big Pharmas in tow
Jan 28, 2025 7:00am
AbbVie crafts $1.6B deal with molecular glue biotech Neomorph
Jan 23, 2025 9:58am
Biogen shrinks research team, prioritizes external innovation
Jan 22, 2025 4:10pm
